IT1299173B1 - The topical ophthalmic use of thalidomide and its derivatives in the medicinal composition for antiangiogenetic activities
- Google Patents
The topical ophthalmic use of thalidomide and its derivatives in the medicinal composition for antiangiogenetic activities
Info
Publication number
IT1299173B1
IT1299173B1IT98RM000271AITRM980271AIT1299173B1IT 1299173 B1IT1299173 B1IT 1299173B1IT 98RM000271 AIT98RM000271 AIT 98RM000271AIT RM980271 AITRM980271 AIT RM980271AIT 1299173 B1IT1299173 B1IT 1299173B1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferdinando Ippolito, Passi Sirio, Carlo Aldo DifiledCriticalFerdinando Ippolito
Priority to IT98RM000271ApriorityCriticalpatent/IT1299173B1/en
Publication of ITRM980271A0publicationCriticalpatent/ITRM980271A0/en
Publication of ITRM980271A1publicationCriticalpatent/ITRM980271A1/en
Application grantedgrantedCritical
Publication of IT1299173B1publicationCriticalpatent/IT1299173B1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
The topical ophthalmic use of thalidomide (α-phthalimidoglutarimide acid or N-phthaloyl glutarimide) is the appropriate composition or the ocular pathology that responds to the antiangiogenetic activities.
IT98RM000271A1998-04-271998-04-27The topical ophthalmic use of thalidomide and its derivatives in the medicinal composition for antiangiogenetic activities
IT1299173B1
(en)
Use of (S) -atenosyl-L-methionine (SAMe) and its physiologically acceptable salts for the treatment of reperfusion injury due to transient focal ischemia